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Novel mechanisms for the treatment of AML before and after transplant
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Acute myeloid leukemia (AML) is a molecularly and cytogenetically complex disease
that has proven difﬁcult to treat with a plateau in long-term disease-free survival over the
last several decades of less than 30% at 5 years. In the past ﬁve years, a number of novel
agents and combinations have been FDA approved for the treatment of AML. The
understanding of novel mechanisms which can be therapeutically targeted for the
treatment of AML continues to expand rapidly. In addition attempts to exploit the
immune system as a mechanism treat leukemia is expanding beyond allogeneic
hematopoietic stem cell transplantation (HSCT) to check point inhibition and T-cell
therapies such as BiTE and CAR-T technology. This has led to an increasing number of
clinical trials in the treatment of AML as well as in the area of maintenance therapy after
intensive induction or consolidative transplantation.
The goal of this Research Topic was to explore novel pathways in AML which could
be exploited for therapy of either upfront or relapse/refractory AML as well as in the
maintenance setting including maintenance therapy post allogeneic transplantation.
Seven manuscripts in this topic explore a variety of aspects AML therapy, ﬁve of
which focus on allogeneic transplantation including maintenance. In the ﬁrst of the
papers that focus on non-transplant therapy, Alotaibi et al. describe a series of cases of
AML treated with FLT3 inhibitors which developed BCR-ABL1 mutations. This
mutation provides an alternative therapeutic target and identifying this mutation at
relapse after FLT3 inhibitor failure should be a priority. In the second paper focusing on
relapsed AML therapy, Watts et al. introduce a CD3xCD123 bispeciﬁc antibody
(APVO436). This paper explored the therapeutic and pharmacodynamic effects of
APVO436 in 14 relapsed/refractory AML/MDS patients who failed treatement with
hypomehylating agents +/- venetoclax. With single agent use at a range of dose levels, in
vivo immunomodulatory and anti-leukemic activity was demonstrated via T-cell
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relapsed mortality. This paper supports the value of hschimerism for directing DLI after alloSCT and warrants
exploration in larger populations across multiple centers.
The ﬁnal two manuscripts in the Research topic provide
comprehensive reviews of post-transplant maintenance therapy
for AML after allogeneic HSCT. Manobianco et al. discuss the
mechanisms of treatment being targeted for post-transplant
maintenance therapy for AML. This includes a discussion of
FLT3 inhibitors, histone deacetylase inhibitors, IDH1 & 2
inhibitors, hypomethylating agents, bcl2 inhibitors, and
checkpoint inhibitors. The review includes data for their use as
well as a discussion of recruiting clinical trials. Nayak and Chen
review these agents as well as hedgehog inhibitors and other
immunomodulatory agents such as lenalidomide.
The manuscripts presented in this Research Topic provide
hope for novel treatments for acute myeloid leukemia before and
after transplant, but also highlight the desperate need for
expanding our repertoire to treat this complicated disease with
a mortality rate of nearly 70% which has not improved over the
last decades despite an array of novel therapies.

activation as well as a median overall survival of 282 days. This
paper supports further investigation of the potential beneﬁts
of APVO436.
Five manuscripts focus on allogeneic stem cell transplantation
ranging from conditioning regimens through DLI to reviews of
maintenance options post-transplant. Wang et al. presented a case
study of stem cell transplantation using a decitabine-containing
preconditioning regimen in TP53 mutated myelodysplastic
syndrome. Nine TP53 mutated patients received decitabine
preconditioning followed by myeloablative allogeneic HSCT.
89% of patients were alive and progression free at a median
follow up of 42 months. Given the extremely poor prognosis of
TP53 mutated myeloid malignancy patients, this preliminary
evidence of efﬁcacy by decitabine containing conditioning
regimens should be explored in larger populations.
Salhotra and Stein. presented a review article that discussed
the role of newer radiation based conditioning regimens such as
total marrow irradiation (TMI) in patient with high-risk AML
undergoing allogenic HSCT in remission or with active disease.
They also discuss mechanisms associated with leukemia relapse
and treatment options available after relapse following alloHSCT using intensiﬁed conditioning regimens. This
comprehensive review provides background on currently used
radiation and chemotherapy preparative regiments as well as
describing new techniques to deliver radiation using total
marrow and lymphoid irradiation which allow for better
disease control and improved clinical outcomes. However,
relapse remains the primary cause of transplant failure so they
further discuss adoptive immunotherapy and maintenance
therapies to improve relapse-free outcomes.
In a brief research report by Stadler et al., the use of
preemptive and therapeutic donor lymphocyte infusion
(preDLI and tDLI) in relapsed myeloid malignancies is
explored when using a novel, quantitative PCR-based highsensitivity chimerism (hs-chimerism). This technique allows
for redicition of relapse more than a month before clinical
diagnosis. They compared a historic cohort of patients who
received preDLI or tDLI prior to hs-chimerism to 32 patients
who received these therapies after. At 2 years from ﬁrst DLI the
hs-chimerism group had a very impressive overall and diseasefree survival, early 3 times that of controls. This was a result of
both reduced relapse incidence with a larger proportion of
patients receiving preemptive DLI as well as decreased non-
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